Market Place
Sourcing Support
All News #Library
Rare Diseases
Santhera Reveals AIFA Board Approval For Agamree Reimbursement
28 Apr 2026 //
GLOBENEWSWIRE
AGAMREE Shows Long-Term Safety, Efficacy in Duchenne Disease
09 Mar 2026 //
GLOBENEWSWIRE
Catalyst Pharma Presents Duchenne Muscular Dystrophy Data
06 Mar 2026 //
GLOBENEWSWIRE
Santhera Proposes AGAMREE® Inclusion In Spain`s Health System
27 Feb 2026 //
GLOBENEWSWIRE
Santhera Proposes AGAMREE Inclusion In Spain`s Health System
27 Feb 2026 //
GLOBENEWSWIRE
Santhera Secures Swissmedic Approval for AGAMREE in DMD
15 Jan 2026 //
GLOBENEWSWIRE
Nxera Pharma Licenses Vamorolone For Duchenne Muscular Dystrophy
08 Jan 2026 //
GLOBENEWSWIRE
AGAMREE (Vamorolone) Shows Safer Profile In DMD Patients
04 Nov 2025 //
PHARMIWEB
Santhera Partners Biomedica For AGAMREE® Distribution In Russia
09 Oct 2025 //
GLOBENEWSWIRE
Santhera Gets Canada Approval For AGAMREE® In DMD
03 Oct 2025 //
GLOBENEWSWIRE
Santhera, Ikris Ink Deal to Distribute AGAMREE in India
29 Aug 2025 //
CONTRACTPHARMA
Santhera, Uniphar Agree to Distribute AGAMREE in 5 GCC Countries
19 Aug 2025 //
GLOBENEWSWIRE
Santhera to update on AGAMREE® rollout at Capital Markets Day
24 Mar 2025 //
GLOBENEWSWIRE
Santhera`s drug gets US FDA nod for rare muscular dystrophy
27 Oct 2023 //
GLOBENEWSWIRE
Santhera Enters into Excl License Agreement with Sperogenix for Vamorolone
03 Jan 2022 //
GLOBENEWSWIRE
Idorsia sheds surplus DMD therapy to Santhera
21 Nov 2018 //
FIERCE BIOTECH
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.